progression to worsening of his alzheimer s disease. we ve been targeting alzheimer s disease at the end stage when people have dementia and can no longer take care of themselves and theplaque and tangles have built up. there could be risks and this one draws red flags. we have known for many years that almost all of the drugs in this class there could be a side effect of aria. dr. sharon cohen has been studying alzheimer s drugs for 20 years and was part of the clinical trial. what she is talking about is amyloid imaging related abnormality. it can look like this or this. it s brain swelling or brain bleeding. though cohen says these types of side effects were mostly mild in the trial. we do know that lecanemab has a low rate of causing macro